Palvella Therapeutics Inc (PVLA)
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious and rare genetic skin diseases. Its lead candidate, QTORIN rapamycin, is a 3.9% anhydrous topical gel being evaluated in Phase 3 testing for microcystic lymphatic malformations and in Phase 2 trials for cutaneous venous malformations. The company is also studying QTORIN rapamycin for angiokeratomas and other mTOR-driven skin disorders, while QTORIN pitavastatin is being developed for disseminated superficial actinic porokeratosis. Palvella Therapeutics is based in Wayne, Pennsylvania, and its common stock trades on the NASDAQ under the symbol PVLA.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PVLA
|
$140.61
|
-11.1% Downside
|
Fair
|
$230.53
|
45.8% Upside
|
Undervalued
|
Fair
|
0.0%
|
November 17, 2026
|
10.2x
|
2.278 B
|
1.982 B
|
1.0%
|
73.9%
|
35.6
|
59.2%
|
